SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 761.71+0.8%3:09 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (1951)12/12/2016 5:00:54 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
Biotech Jim

  Read Replies (1) of 3559
 
Unfortunately for OPHT, two P3 Fovista trial demonstrate no benefit adding anti-PDGF-bb aptamer to anti-VEGF regime to Lucentis for wAMD.

finance.yahoo.com

For now expansion of the anti-VEGF treatment regimen (treatment duration in controlling vision loss) for wAMD and DME will not be supported by this combination. Maybe anti-ANG2 mechanisms may work better. By mid-2017 we may have idea is there new advancement in treatment of wAMD.

OPHT down to ~10, REGN up to ~390 level.

Hope Sanofi can fix manufacturing problems before JPM bio-conference.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News